Under the same schedule, in the HER2-PDXR model EGCG (30 mg/kg for 3d/w) and pertuzumab (30 mg/kg/once weekly) also reduced tumor growth after 24 days of treatment (Fig 4A, right panel), but in vivo efficacy of the dual FASN and HER2 blockade was also superior (and more rapid) compared with EGCG and pertuzumab as a single agents. Here, FASN is linked to neoplasm.